As suggested by Aledort [15] a move towards harmonization would permit meta-analyses of available data and represent Luminespib cost a major step towards statistically and clinically valid assessment of the risk of haemophilia treatment, especially that of inhibitor development.

I am grateful to Françoise Rossi from the International Plasma Fractionation Association (IPFA) who supplied me with useful information on CPMP guidelines and useful criticism and advice on the text of this article. In the last 2 years, the author has been acting as consultant in education activities for the Bayer Awards, and has received honoraria for speaking at meetings organized by Bayer, Biotest, Grifols, Novo Nordisk and Pfizer. “
“Several risk factors for inhibitors have recently been described for haemophilia A. It has been assumed that similar risk factors are also relevant for haemophilia B, but there is limited data to confirm this notion. The aim of this study was to determine the prevalence of and risk factors associated with inhibitors

in haemophilia B. The database of the Universal Data Collection (UDC) project of the Centers for Disease Control for the years 1998–2011 was queried to determine the prevalence of inhibitors in haemophilia B subjects. In addition, disease severity, race/ethnicity, age, factor exposure and prophylaxis usage were evaluated to determine their impact on inhibitor prevalence. Of the 3785 male subjects with haemophilia B enrolled in the UDC database, 75 (2%) were determined to have an inhibitor at some point Opaganib datasheet during the study period. Severe disease (OR 13.1, 95% CI 6.2–27.7), black race (OR 2.2, 95% CI 1.2–4.1), and age <11 years (OR 2.5, 95% CI 1.5–4.0) were found to be significantly associated with having an inhibitor. There was insufficient data to determine if type of factor used and prophylaxis were associated with inhibitors.

Inhibitors in haemophilia B are much less prevalent than haemophilia A, especially in patients with mild disease. Similar factors associated with inhibitors in haemophilia A also seem to be present for haemophilia Non-specific serine/threonine protein kinase B. The information collected by this large surveillance project did not permit evaluation of potential risk factors related to treatment approaches and exposures, and additional studies will be required. “
“Haemophilia carriers and women with inherited bleeding disorders (IBD) experience menorrhagia, bleed following dentistry, surgery, injury or childbirth. Symptoms are easily treated leading to full and active lives. Nevertheless, some girls and women suffer with abnormal bleeding for many years before diagnosis. We explored the experiences of girls and young women (aged 9–34 years) with IBD by means of focus groups which consisted of moderated discussion addressing specific aspects of bleeding, management and coping strategies.